REG - Redx Pharma plc - Result of Annual General Meeting

Redx PharmaAnnouncement

14/03/2023 11:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230314:nRSN9334Sa&default-theme=true

RNS Number : 9334S  Redx Pharma plc  14 March 2023

REDX PHARMA PLC

("Redx" or "the Company")

 

Result of Annual General Meeting

Alderley Park, UK, 14 March 2023 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, highly targeted therapeutics for the treatment of cancer and
fibrotic disease announces that its Annual General Meeting was held at 11am on
14 March 2023, with all resolutions passed by substantial majorities.

 

The table below sets out the details of the votes put to shareholders

 

 Resolution number  Resolution name                                Number of votes for & discretionary      % of votes for & discretionary      Number of votes against  % of votes against  % of votes withheld*  Total votes cast (including withheld)
 1                  Receive the Company's annual accounts          306,243,523                              94.91%                              16,434,331               5.09%               0.00%                 322,680,605
 2                  Re-appoint Ernst & Young as auditors           322,677,854                              100.00%                             2,751                    0.00%               0.00%                 322,680,605
 3                  Re-elect Dr Bernhard Kirschbaum as a director  306,241,648                              94.91%                              16,436,206               5.09%               0.00%                 322,680,605
 4                  Re-elect Lisa Anson as a director              322,678,730                              100.00%                             1,875                    0.00%               0.00%                 322,680,605
 5                  Re-elect Natalie Berner as a director          322,673,730                              100.00%                             6,875                    0.00%               0.00%                 322,680,605
 6                  Authorise the directors to allot shares        322,551,347                              99.96%                              125,732                  0.04%               0.00%                 322,680,605
 7                  Disapply pre-emption rights                    322,545,847                              99.96%                              133,983                  0.04%               0.00%                 322,680,605

*A vote withheld is not a vote in law and is not counted in the calculation of
the proportion of votes 'For' or 'Against'

 For further information, please contact:

 Redx Pharma Plc                                                      T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)                          T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                                       T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                           T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                       T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

 

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic disease and the emerging
area of cancer-associated fibrosis, aiming initially to progress them to
clinical proof of concept before evaluating options for further development
and potential value creation. The Company's lead fibrosis product candidate,
the selective ROCK2 inhibitor RXC007, is in development for interstitial lung
disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis (IPF)
in October 2022, with topline data expected in Q1 2024. Redx's lead oncology
product candidate, the Porcupine inhibitor RXC004, being developed as a
targeted treatment for Wnt-ligand dependent cancers, is expected to report
both monotherapy and combination with anti-PD-1 Phase 2 data during 2023.
Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the
treatment of fibrostenotic Crohn's disease, is progressing towards a CTA/IND
application at the end of 2023.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a
non-covalent (reversible) BTK inhibitor now approved by the US FDA for adult
patients with mantle cell lymphoma previously treated with a covalent BTK
inhibitor, and AZD5055/RXC006, a Porcupine inhibitor targeting fibrotic
diseases including IPF, which AstraZeneca is progressing in a Phase 1 clinical
study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals,
which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now
progressing through Phase 1 clinical studies, and an early stage oncology
research collaboration.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGDZGMFMDMGFZM